4.6 Article

Simple Measurement of IgA Predicts Immunity and Mortality in Ataxia-Telangiectasia

Journal

JOURNAL OF CLINICAL IMMUNOLOGY
Volume 41, Issue 8, Pages 1878-1892

Publisher

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-021-01090-8

Keywords

Ataxia-telangiectasia; IgA deficiency; Immunoglobulins; Immunodeficiency; Lymphopenia; Mortality

Categories

Funding

  1. Projekt DEAL
  2. German Federal Ministry of Education and Research (BMBF) [01GM0896, 01GM1111B, 01GM1517C, 01EO1303, 01ZZ1801B]
  3. EU [HEALTHF2-2008-201549]
  4. Novartis
  5. GlaxoSmithKline
  6. LFB
  7. UCB UK
  8. Plasma Protein Therapeutics Association (PPTA),
  9. Care-for-Rare Foundation
  10. PROimmune e.V
  11. Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [39087428]
  12. UK National Institute of Health Research
  13. Great Ormond Street Hospital Biomedical Research Centre

Ask authors/readers for more resources

The study analyzed mortality and immunity data of patients with ataxia-telangiectasia (A-T) in relation to IgA deficiency, finding that patients with IgA deficiency have significantly lower survival rates, lymphocyte counts, and subsets compared to A-T patients without IgA deficiency. This suggests that IgA deficiency may indicate a poorer prognosis for classical A-T patients.
Patients with ataxia-telangiectasia (A-T) suffer from progressive cerebellar ataxia, immunodeficiency, respiratory failure, and cancer susceptibility. From a clinical point of view, A-T patients with IgA deficiency show more symptoms and may have a poorer prognosis. In this study, we analyzed mortality and immunity data of 659 A-T patients with regard to IgA deficiency collected from the European Society for Immunodeficiencies (ESID) registry and from 66 patients with classical A-T who attended at the Frankfurt Goethe-University between 2012 and 2018. We studied peripheral B- and T-cell subsets and T-cell repertoire of the Frankfurt cohort and survival rates of all A-T patients in the ESID registry. Patients with A-T have significant alterations in their lymphocyte phenotypes. All subsets (CD3, CD4, CD8, CD19, CD4/CD45RA, and CD8/CD45RA) were significantly diminished compared to standard values. Patients with IgA deficiency (n = 35) had significantly lower lymphocyte counts compared to A-T patients without IgA deficiency (n = 31) due to a further decrease of naive CD4 T-cells, central memory CD4 cells, and regulatory T-cells. Although both patient groups showed affected TCR-ss repertoires compared to controls, no differences could be detected between patients with and without IgA deficiency. Overall survival of patients with IgA deficiency was significantly diminished. For the first time, our data show that patients with IgA deficiency have significantly lower lymphocyte counts and subsets, which are accompanied with reduced survival, compared to A-T patients without IgA deficiency. IgA, a simple surrogate marker, is indicating the poorest prognosis for classical A-T patients. Both non-interventional clinical trials were registered at clinicaltrials.gov 2012 (Susceptibility to infections in ataxia-telangiectasia; NCT02345135) and 2017 (Susceptibility to Infections, tumor risk and liver disease in patients with ataxia-telangiectasia; NCT03357978)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available